These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23527672)

  • 21. 153Sm-EDTMP.
    Rodriguez V; Betcher D
    J Pediatr Oncol Nurs; 1998 Apr; 15(2):95-7. PubMed ID: 9597818
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
    Higano CS; Quick DP; Bushnell D; Sartor O
    Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.
    Paravati AJ; Russo AL; Aitken C
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):506-10. PubMed ID: 20888141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer.
    Papatheofanis FJ; Smith C; Najib M
    Am J Ther; 2009; 16(2):127-32. PubMed ID: 19300039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
    Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
    J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients.
    Parlak Y; Gumuser G; Sayit E
    Radiat Prot Dosimetry; 2015 Mar; 163(4):468-72. PubMed ID: 25063786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
    Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
    Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium.
    Krishnamurthy GT; Krishnamurthy S
    J Nucl Med; 2000 Apr; 41(4):688-91. PubMed ID: 10768570
    [No Abstract]   [Full Text] [Related]  

  • 29. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
    Dolezal J; Vizd'a J; Cermáková E
    Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [153Sm-EDTMP for moderate and severe bone cancer pain].
    Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of painful bony metastases with Samarium 153-EDTMP in prostate carcinoma].
    Mhiri A; Hassad R; Sellem A; Bahri H; Diakite R; Slim I; Mahersi M; Hammami H; Ben Adallah M; Ben Slimene MF
    Tunis Med; 2007 Jul; 85(7):580-5. PubMed ID: 18064991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
    Serafini AN
    Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
    Weiss K; Köck HH; Atefie K; Sinzinger H
    Rev Esp Med Nucl; 2001 Jun; 20(4):311-2. PubMed ID: 11940421
    [No Abstract]   [Full Text] [Related]  

  • 34. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP.
    Sinzinger H; Weiss K; Hiltunen J
    Anticancer Res; 2009 Aug; 29(8):3393-5. PubMed ID: 19661362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
    J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
    Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
    Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Metabolic radiotherapy: what role will it have in 2001?].
    George B; Douard MC; Rain JD
    Cancer Radiother; 2002 May; 6(3):188-200. PubMed ID: 12116845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer].
    Ratsimanohatra H; Barlesi F; Doddoli C; Robitail S; Gimenez C; Kleisbauer JP; Astoul P
    Rev Mal Respir; 2005 Apr; 22(2 Pt 1):317-20. PubMed ID: 16092169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases.
    Baczyk M; Milecki P; Pisarek M; Gut P; Antczak A; Hrab M
    Neoplasma; 2013; 60(3):328-33. PubMed ID: 23374004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bone metastases treated with radiopharmaceuticals].
    Giammarile F
    Bull Cancer; 2013 Nov; 100(11):1223-7. PubMed ID: 24409472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.